Last reviewed · How we verify
IPP-201101
IPP-201101 is an immunomodulatory compound designed to enhance immune responses against disease targets.
At a glance
| Generic name | IPP-201101 |
|---|---|
| Also known as | Lupuzor, regiremod |
| Sponsor | ImmuPharma |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As an investigational immunopharmaceutical from ImmuPharma, IPP-201101 is being developed to modulate immune function. The specific molecular mechanism and target remain proprietary or not fully disclosed in public literature, though the company's focus suggests potential application in autoimmune or oncologic indications where immune modulation is therapeutically relevant.
Approved indications
Common side effects
Key clinical trials
- A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus (PHASE3)
- Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPP-201101 CI brief — competitive landscape report
- IPP-201101 updates RSS · CI watch RSS
- ImmuPharma portfolio CI